BioXcel Therapeutics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell BTAI and other ETFs, options, and stocks.

About BTAI

BioXcel Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of artificial intelligence solutions in neuroscience and immuno-oncology. It also focuses on utilizing technology and research to develop therapeutics solutions. 

CEO
Vimal D. Mehta
CEOVimal D. Mehta
Employees
29
Employees29
Headquarters
New Haven, Connecticut
HeadquartersNew Haven, Connecticut
Founded
2017
Founded2017
Employees
29
Employees29

BTAI Key Statistics

Market cap
5.68M
Market cap5.68M
Price-Earnings ratio
-0.04
Price-Earnings ratio-0.04
Dividend yield
Dividend yield
Average volume
7.02M
Average volume7.02M
High today
$0.3801
High today$0.3801
Low today
$0.1569
Low today$0.1569
Open price
$0.2122
Open price$0.2122
Volume
58.56M
Volume58.56M
52 Week high
$4.29
52 Week high$4.29
52 Week low
$0.1569
52 Week low$0.1569

Stock Snapshot

As of today, BioXcel Therapeutics(BTAI) shares are valued at $0.17. The company's market cap stands at 5.68M, with a P/E ratio of -0.04.

On 2026-08-31, BioXcel Therapeutics(BTAI) stock traded between a low of $0.16 and a high of $0.38. Shares are currently priced at $0.17, which is +9.6% above the low and -54.8% below the high.

The BioXcel Therapeutics(BTAI)'s current trading volume is 58.56M, compared to an average daily volume of 7.02M.

During the past year, BioXcel Therapeutics(BTAI) stock moved between $0.16 at its lowest and $4.29 at its peak.

During the past year, BioXcel Therapeutics(BTAI) stock moved between $0.16 at its lowest and $4.29 at its peak.

BTAI News

Benzinga 3d
Deal Dispatch: Carets Corp Explores Strategic Alternatives, nVent Electric Buys Maverick Power for $1.75 - Benzinga

...

Deal Dispatch: Carets Corp Explores Strategic Alternatives, nVent Electric Buys Maverick Power for $1.75 - Benzinga
Benzinga 3d
BioXcel Stock Plunges: Chapter 11 Filing Triggers Teva Stalking Horse Bid

BioXcel Therapeutics, Inc. (NASDAQ:BTAI) shares plunged on Friday as the company commenced voluntary Chapter 11 proceedings tied to a court-supervised asset sal...

BioXcel Stock Plunges: Chapter 11 Filing Triggers Teva Stalking Horse Bid
TipRanks 3d
BioXcel Therapeutics Initiates Chapter 11 and Sale Process

The latest update is out from Bioxcel Therapeutics ( (BTAI) ). On August 27, 2026, BioXcel Therapeutics and two subsidiaries filed voluntary Chapter 11 petitio...

More BTAI News

TipRanks 3d
Teva unit bids to acquire neuroscience product from BioXcel Therapeutics

Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries (TEVA) announced it has made a bid to acquire an innovative neuroscience...

TipRanks 6d
BioXcel Therapeutics Amends Credit Agreement Amid Liquidity Strain

Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions Subscribe to TipRanks Smart Investor Newsletter, and...

People also own

Based on the portfolios of people who own BTAI. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.